Indication: The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among participants who are in the subpopulation of
participants who were not expected to receive standard-of-care COVID-19 Group A therapy (defined as monoclonal antibody [mAb] treatment or outpatient
intravenous [IV] remdesivir).
Frequency of Visit: Screening Visit: 1 In Person Visit: 11
Age: 18 to 64 years old
Study Number: 004
Study Requirement: *Must have TESTED POSITIVE for COVID-19 *Have had COVID-19 symptoms start within the past 5 days
Stipend: Compensation provided to both Subject and Informant